RARE — Ultragenyx Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $1.50bn
- $2.35bn
- $673.00m
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx
Ultragenyx rises after FDA nod for rare disorder drug
Ultragenyx climbs after US FDA approves gene therapy
Ultragenyx up after US FDA approves gene therapy
Ultragenyx sets $3.95 million price for rare disease gene therapy (updated)
US FDA approves Ultragenyx's gene therapy for rare disorder
U.S. STOCKS ON THE MOVE-Principal Financial Group, NetApp
U.S. STOCKS ON THE MOVE-Genesco, Fervo Energy, Tyson Foods
Ultragenyx hits record low after rare disease drug trial failure
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial (updated)
U.S. STOCKS ON THE MOVE-Gold miners, Polestar Automotive, Nvidia
U.S. STOCKS ON THE MOVE-Snowflake, Ultragenyx Pharmaceutical, Broadcom
Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial
Ultragenyx Pharma plunges after rare disease drug trial failure
U.S. RESEARCH ROUNDUP-Broadcom, Deere & Co, Snowflake
Ultragenyx's rare disease drug fails in late-stage trial; shares plunge (updated)